Developer docs
API playgroundTry for free, no card

Search company profiles

Hyloris Pharmaceuticals

Full company profile

uuid00036q5

Namestring
Hyloris Pharmaceuticals
Legal namestring
Hyloris Pharmaceuticals NV/SA
Websiteurl
hyloris.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Hyloris Pharmaceuticals NV/SA is a Belgian specialty pharmaceutical company founded in 2012 and headquartered in Liège, listed on Euronext Brussels (HYL) since June 2020. The company's strategy is to reinvent existing approved medications through reformulation, repurposing, and select new chemical entities, primarily leveraging the FDA's 505(b)(2) regulatory pathway (or equivalents), which reduces clinical burden and development cost versus de novo drug discovery. Proprietary formulation platforms span ready-to-use intravenous formulations, taste-masked oral liquids, and extended-release oral delivery systems, with patent and application coverage extending into the 2035–2046 range.\n\nThe commercial portfolio currently comprises four royalty-generating assets — Maxigesic IV (a fixed-dose paracetamol/ibuprofen IV for post-operative pain, partnered worldwide with AFT Pharmaceuticals and commercialized by Hikma in the US as Combogesic IV), Sotalol IV (AltaThera, US), Podofilox Gel (Padagis, US, launched December 2023), and Tranexamic Acid RTU (Avenacy, US launch H1 2026). Beyond these, the disclosed pipeline numbers 28 announced candidates (more than 30 product candidates in total) across hospital acute care, swallow-impaired populations (pediatric, geriatric, immunocompromised), women's health and urology, orphan/rare diseases (Wilson's disease, AML, LVAD-associated right heart failure), and specialty therapeutic areas; the pipeline is structured into Mavericks (high-clinical-evidence), Core Drivers (near-term revenue catalysts), and Promising Seeds (early-stage).\n\nHyloris operates an asset-light, partner-driven commercialization model: it retains development and regulatory ownership while licensing out or partnering distribution with established pharma players (AFT Pharmaceuticals, Hikma, AltaThera, Padagis, Avenacy, Orion, Rosemont, Grand Life Sciences, Huons, Kuvatris, Purna Female Healthcare, Vaneltix, Wake Forest, ArborMed, RedHill). Revenue mechanics are licensing royalties, milestones (e.g., up to $60M from the RedHill RHB-102 deal), and license/collaboration fees, supplemented by episodic non-dilutive grants from the Walloon Region; the company is EBITDA-negative and reinvests into pipeline expansion through both organic R&D and in-licensing/acquisitions.\n

Short descriptiontext

Hyloris Pharmaceuticals is a Belgian specialty pharma that develops reformulated, repurposed, and select NCE medicines using the FDA 505(b)(2) pathway, commercializing them globally through licensing partners across hospital, women's health, rare disease, and orphan indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLiège, Belgium
HQ citystring
Liège
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
reformulated pharmaceuticals, specialty pharmaceutical development, 505(b)(2) regulatory pathway, intravenous drug formulations, pharmaceutical licensing partnerships
Industry4 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Royalty Income from Partnered Products
TypeLicensing Royalties
Description

Three partnered commercial-stage products generate royalty income: Sotalol IV (FDA-approved, commercialized by AltaThera in US), Maxigesic IV (licensed in 100+ countries, marketed in 30+ countries), and Podofilox Gel (FDA approved, launched by Padagis in December 2023). Tranexamic Acid IV RTU also recently approved in US with launch planned for first half 2026.

hyloris.com
2Milestone Payments
TypeLicensing Royalties
Description

Up to $60 million in potential milestone payments plus royalties from licensing RHB-102 (Bekinda) to Hyloris from RedHill Biopharma, demonstrating potential for additional milestone-based revenue from product acquisitions.

stocktitan.net
3Equity Financing
TypeSubscription Recurring
Description

The company raised EUR 15.0 million in April 2022 through private placement to fund development of new product candidates and accelerate in-house R&D activities. Additional non-dilutive funding of EUR 1 million received from Walloon Region for HY-083 development.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Products commercialized through partner network; pricing managed by distribution partners
ModelOtherBilling cadenceOther
Notes

Hyloris does not sell directly to end customers. Products are commercialized through pharmaceutical distribution partners (e.g., Hikma for Combogesic IV in US, AltaThera for Sotalol IV, Padagis for Podofilox Gel). Pricing varies by market and partner agreements.

hyloris.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Maxigesic IV
Description

Differentiated proprietary intravenous fixed-dose combination of paracetamol and ibuprofen for post-operative pain treatment, partnered worldwide with AFT Pharmaceuticals

hyloris.com
+3 more records
Core offering1 text field

Hyloris Pharmaceuticals is a specialty pharmaceutical company that develops reformulated, repurposed, and new chemical entity (NCE) medicines primarily using the FDA's 505(b)(2) regulatory pathway. Its proprietary portfolio spans more than 30 products including ready-to-use (RTU) intravenous formulations, taste-masked oral liquids, extended-release oral formulations, and novel drug delivery systems across hospital/acute care, women's health, cardiology, and rare diseases. Four commercial products (Maxigesic IV, Sotalol IV, Podofilox Gel, and Tranexamic Acid RTU) generate royalty income through pharmaceutical partners worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Maxigesic IV licensed in more than 100 countries, approved in over 50 countries, marketed in more than 30 countries
+2 more records
Product overview1 text field

Hyloris Pharmaceuticals is a specialty pharma company with a broad portfolio of reformulated, repurposed, and new chemical entity (NCE) medicines organized across three strategic focus groups: Mavericks (high-potential products with clinical evidence), Core Drivers (catalyst products building near-term recurring revenue), and Promising Seeds (early-stage products pending clinical validation). The company has 4 commercial products delivering royalty income: Maxigesic IV (non-opioid post-operative pain), Sotalol IV (atrial fibrillation), Podofilox Gel (HPV warts), and Tranexamic Acid RTU (bleeding). Beyond the 28 publicly announced products, Hyloris has initiated additional early-stage development activities, bringing the total pipeline to more than 30 products. The development strategy primarily leverages the FDA's 505(b)(2) pathway for reformulated pharmaceuticals where safety and efficacy have already been established.

Product and service24 records
1Maxigesic IV
CategoryCommercial Product — Hospital Acute Care / Post-Operative Pain
Description

Proprietary intravenous fixed-dose combination of 1,000 mg paracetamol and 300 mg ibuprofen for effective, opioid-sparing treatment of acute pain in hospital settings. Partnered worldwide with AFT Pharmaceuticals (excluding Australia and New Zealand); commercialized in the U.S. by Hikma under the trade name Combogesic IV. Licensed in 100+ countries, approved in 50+ countries, marketed in 30+ countries.

2Sotalol IV
CategoryCommercial Product — Cardiovascular (Antiarrhythmic)
Description

Intravenous formulation of the established antiarrhythmic sotalol developed to enable safe and efficient initiation of sotalol therapy in patients with atrial fibrillation or ventricular arrhythmias. FDA-approved and commercialized in the U.S. by AltaThera for treatment of documented life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm.

3Podofilox Gel
CategoryCommercial Product — Dermatology / Women's Health
Description

0.5% podofilox topical gel; the first generic equivalent to Condylox gel in the U.S., developed for treatment of external genital and perianal warts caused by HPV. Launched by Padagis in the U.S. in December 2023.

4Tranexamic Acid RTU
CategoryCommercial Product — Hospital Acute Care / Antifibrinolytic
Description

Ready-to-use intravenous formulation of tranexamic acid designed to eliminate the need for reconstitution and dilution prior to administration. FDA-approved in June 2025; exclusive US commercialization partner is Avenacy, with U.S. launch planned for H1 2026; partnered with Orion for European markets.

5HY-094 (Next-Generation IV Iron)
CategoryPipeline Product — Mavericks (IV Iron, Hematology)
Description

Next-generation intravenous iron product candidate and new chemical entity (NCE) for treatment of iron deficiency anemia in adults. Co-developed with AFT Pharmaceuticals for global commercialization and partnered with Grand Life Sciences Group for China. Has completed Phase 2b development and is advancing toward Phase 3 clinical trials. Proprietary IP with exclusive global human-use license secured.

6Milrinone ER
CategoryPipeline Product — Mavericks (Cardiovascular, Orphan)
Description

Proprietary extended-release oral formulation of milrinone for treatment of right heart failure in patients with left ventricular assist devices (LVAD), providing steady-state exposure for long-term use. FDA Orphan Drug Designation received for LVAD-associated RHF indication; priority patent application filed in 2025 with expected expiry in 2046.

7Miconazole DB (Miconazole-Domiphen Bromide)
CategoryPipeline Product — Mavericks (Women's Health / Antifungal)
Description

Dual-action vaginal cream combining miconazole with domiphen bromide for treatment of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV). Dose-finding Phase 2 study in VVC completed. Intellectual property protection through 2038, 2044, and 2045. Developed in partnership with Purna Female Healthcare.

8Suramin IV
CategoryPipeline Product — Mavericks (Neglected Tropical Disease)
Description

Standardized intravenous formulation for Human African Trypanosomiasis (sleeping sickness). In Phase 3 development. May qualify for FDA Priority Review Voucher (HAT is on FDA's tropical diseases list). Phase 2 study on Autism Spectrum Disorder completed. Developed in partnership with Kuvatris Therapeutics.

9Alenura
CategoryPipeline Product — Mavericks (Urology / Pain)
Description

Ready-to-use intravesical therapy combining alkalinized lidocaine with heparin for adults with interstitial cystitis/bladder pain syndrome (IC/BPS) acute pain flares. Currently in Phase 2 clinical development in partnership with Vaneltix. Multiple patents and applications with maximum expiry in 2038.

10TXA Oromucosal Solution (XTRAZA)
CategoryPipeline Product — Core Drivers (Hemostatic Dental Rinse)
Description

Proprietary tranexamic acid oral rinse designed for dental procedures in patients taking anticoagulants. Randomized, double-blind, multicenter, placebo-controlled Phase 3 trial ongoing with results expected in 2026. U.S. patents granted and pending; expected expiry in 2039. Partnered with Colonis Pharma (UK), Huons Co., Ltd. (South Korea), and AFT Pharmaceuticals in various territories.

11Metolazone IV
CategoryPipeline Product — Core Drivers (Cardiorenal)
Description

First injectable formulation of metolazone designed for hospital use in patients with acute decompensated heart failure and severe fluid overload. Registration batches initiated, clinical completion anticipated in 2026. Patents and pending applications including lyophilized formulation protection; expiry 2044.

12Valacyclovir Oral Suspension
CategoryPipeline Product — Core Drivers (Antiviral, Taste-Masked)
Description

Differentiated valacyclovir powder for oral suspension designed for patients who have difficulty swallowing tablets. NDA submitted to FDA, Complete Response Letter received due to manufacturing-site issues at the third-party manufacturer; launch timing may shift to 2027. Proprietary formulation protected by U.S. patents expiring 2035 and 2036 and pending applications expected to extend to 2045.

13Atomoxetine Oral Liquid
CategoryPipeline Product — Core Drivers (ADHD, Taste-Masked Liquid)
Description

Reformulated easy-to-dose version of atomoxetine for ADHD treatment designed for patients who struggle to swallow capsules. NDA filed with FDA in early 2026 by commercial partner Rosemont Pharmaceuticals. Multiple patents and pending applications providing potential protection through 2044.

14Ondansetron ER
CategoryPipeline Product — Core Drivers (Antiemetic, Extended-Release)
Description

Once-daily extended-release oral formulation of ondansetron combining immediate-release and extended-release components for nausea and vomiting associated with chemotherapy, radiotherapy, and post-operative recovery. Acquired from RedHill Biopharma alongside the licensing of RHB-102 (Bekinda).

15Dofetilide IV
CategoryPipeline Product — Core Drivers (Antiarrhythmic IV)
Description

Differentiated intravenous formulation of dofetilide for treatment of atrial fibrillation and atrial flutter. Pivotal clinical trial completed successfully; U.S. regulatory submission expected Q2 2026. Patents granted with expiry dates between 2039 and 2043, including one-day loading approaches.

16Phosphate Oral Liquid (HY-088)
CategoryPipeline Product — Core Drivers (Electrolyte Oral Liquid)
Description

Oral liquid phosphate product (HY-088) designed to improve treatment of hypophosphatemia through a standardized ready-to-use formulation. First European regulatory filing planned for late H1 2026. Pending patent applications with expected expiry in 2045 and 2046.

17Pantoprazole IV RTU
CategoryPipeline Product — Core Drivers (PPI IV, RTU)
Description

Differentiated, ready-to-use IV pantoprazole product designed to replace current lyophilized formulations. Partnership with Orion for European markets announced January 2026. Pending U.S. and international patent applications; expected expiry 2045.

18HY-074 (IV Antiplatelet for Acute Coronary Syndrome)
CategoryPipeline Product — Core Drivers (Cardiovascular IV)
Description

Novel intravenous formulation of a widely used oral antiplatelet therapy for acute coronary syndrome. Registration batches produced; pivotal clinical trial planned for 2026. Patent applications filed with maximum expected expiry in 2043–2044.

19Aspirin IV
CategoryPipeline Product — Core Drivers (Cardiovascular IV)
Description

Intravenous formulation of acetylsalicylic acid designed to provide rapid and reliable antiplatelet activity in acute coronary syndrome. Pivotal study completed successfully with FDA alignment on regulatory pathway; submission planned for 2026. Multiple U.S. patents on aspirin compositions with expiry 2038-2039.

20Fusidic Acid Topical Cream
CategoryPipeline Product — Core Drivers (Topical Antibiotic)
Description

Topical antibiotic cream containing 2% fusidic acid; generic equivalent to Fucidin cream for treatment of bacterial skin infections. Regulatory submission in Canada expected in 2026.

21HY-083 (Idiopathic Rhinitis Intranasal Spray)
CategoryPipeline Product — Promising Seeds (Nasal Spray, NCE)
Description

Potential first-in-class proprietary intranasal spray based on TRPV1 agonist mechanism for treatment of idiopathic rhinitis. Backed by EUR 1 million in non-dilutive funding from the Walloon Region (non-refundable grant plus recoverable cash advance).

22HY-106 Methanobactin (Wilson's Disease)
CategoryPipeline Product — Promising Seeds (Rare Disease, Wilson's)
Description

Novel copper-selective chelator based on methanobactin for treatment of Wilson's disease (a rare inherited metabolic disorder characterized by toxic copper accumulation). First-in-human study planned for 2026. European and Turkish rights licensed from ArborMed.

23HY-086 / PTX-252 (AML Adjunctive Therapy)
CategoryPipeline Product — Promising Seeds (Oncology Orphan, NCE)
Description

Differentiated NCE adjunctive therapy for acute myeloid leukemia (AML) and small cell lung cancer (SCLC). FDA Orphan Drug Designation obtained for AML; Phase 1 preparations underway.

24RHB-102 (Bekinda) License
CategoryLicensed Asset — GI/Oncology Support
Description

Licensed RHB-102 (Bekinda) from RedHill Biopharma for up to $60 million in potential milestone payments plus royalties, targeting GLP-1/GIP receptor agonist therapy-associated GI side effects and oncology support indications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Licensed RHB-102 (Bekinda) from RedHill for up to $60 million in potential milestone payments plus royalties. Also acquired Ondansetron ER (extended-release oral ondansetron) product, broadening pipeline into GI/nausea indications. RedHill also reports $4 million investment from Cumberland Pharmaceuticals for 30% stake in Talicia Holdings Inc.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-19
Description

Strategic partnership for RTU Pantoprazole IV in European markets. Orion is a significant European pharmaceutical company with established commercialization capabilities across the region. Target launch as of 2028.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-30
Description

Licensed European and Turkish rights to next-generation Wilson's disease candidate (HY-106 Methanobactin) from ArborMed. Wilson's disease is a rare inherited metabolic disorder characterized by toxic copper accumulation.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-29
Description

Partnership for Atomoxetine Oral Solution in the US market. Also partnered for Valacyclovir Oral Suspension in US. Atomoxetine NDA filed with US FDA in early 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-12
Description

Collaboration to develop a therapy for a rare skin disorder. This partnership focuses on an exclusive license option for an innovative topical therapy for a rare genetic skin disorder, with potential to qualify for Orphan Drug Designation.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-28
Description

Partnership to bring Tranexamic Acid RTU to key European markets. This complements the January 2026 partnership for Pantoprazole IV RTU.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-27
Description

Partnership for HY-094 (next-generation IV iron product) in China. HY-094 is a new chemical entity for treatment of iron deficiency anemia, currently advancing toward Phase 3 after completing Phase 2b development.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-22
Description

Exclusive licensing agreement for XTRAZA in South Korea. XTRAZA is a proprietary tranexamic acid oral rinse designed for dental procedures in patients taking anticoagulants.

9Kuvatris Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

Partnership to advance Suramin IV development for Human African Trypanosomiasis (sleeping sickness). Since HAT is on FDA's tropical diseases list, approval could qualify for Priority Review Voucher.

hyloris.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-13
Description

Partnership for Valacyclovir Oral Suspension covering the Netherlands. Combined with AFT partnership for Valacyclovir in Australia, New Zealand, and Canada.

11Colonis Pharma
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-03
Description

Partnership for XTRAZA (tranexamic acid oral rinse) in the United Kingdom for prevention and treatment of bleeding in patients on anticoagulant therapy undergoing dental procedures.

hyloris.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-26
Description

Exclusive US commercialization partner for Tranexamic Acid Ready-to-Use (RTU) IV formulation. FDA approval received in June 2025; US launch planned for first half 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-30
Description

Partnership to develop Miconazole-Domiphen Bromide vaginal cream for vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV). Positive Phase 2 trial results announced in January 2024.

14Padagis
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-04
Description

Padagis launched Podofilox Gel (first generic equivalent to Condylox gel) in the US market in December 2023 for treatment of external genital and perianal warts caused by HPV.

hyloris.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-03-31
Description

AFT Pharmaceuticals is a key strategic partner for Maxigesic IV worldwide (excluding Australia and New Zealand). Also co-develops HY-094 (IV iron product for iron deficiency anemia) for global commercialization. Additionally partnered for XTRAZA (tranexamic acid oral rinse) and Valacyclovir in various territories. Maxigesic IV is licensed in 100+ countries, approved in 50+ countries, and marketed in 30+ countries through this partnership network.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-03-31
Description

Hikma commercializes Maxigesic IV in the United States under the registered trade name Combogesic IV. This is a key commercial partnership for the US market, one of the world's largest pharmaceutical markets.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-03-31
Description

AltaThera commercializes Sotalol IV in the US market. Sotalol IV is FDA-approved for treatment of documented life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-17
Description

Strategic partnership for Alenura treatment of acute pain in interstitial cystitis. Alenura is a ready-to-use intravesical therapy combining alkalinized lidocaine with heparin for adults with IC/BPS pain flares.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.S. specialty generic pharmaceutical company focused on oral solids, topicals, and specialty formulations. Similar to Hyloris in pipeline breadth vs. headcount and focus on niche reformulated products.

TypeBroad incumbent
Description

Large multinational specialty pharmaceutical company with broad generics, injectables, and branded pharma portfolio. Comparable to Hyloris as a U.S. commercial partner on Combogesic IV and for overlapping injectable/specialty strategy at greater scale.

TypeRegional player
Description

European-based specialty pharmaceutical company focused on women's health and other specialty therapeutic areas. Comparable to Hyloris's women's health and specialty therapeutic area strategy, primarily serving European markets.

4Padagis
TypeDirect peer
Description

U.S. specialty generics company (formerly Perrigo's generics unit) commercializing topical, oral, and injectable generics. Direct peer given commercial partnership on Podofilox Gel and overlapping focus on value-added generics and specialty pharmaceutical products.

TypeDirect peer
Description

Specialty pharmaceutical company headquartered in New Zealand focused on reformulated and repurposed medicines with global commercialization partnerships. Direct comparable to Hyloris in product strategy and partnership-driven GTM; Hyloris's flagship Maxigesic IV is co-developed with AFT.

TypeBroad incumbent
Description

Global specialty pharmaceutical company with branded and specialty generics franchises, including hospital injectables and reformulated products. Comparable to Hyloris's hospital/acute-care injectable focus.

TypeDirect peer
Description

U.S. specialty pharmaceutical company focused on niche generics, 505(b)(2) products, and contract manufacturing. Closely comparable to Hyloris in reformulation focus, small headcount relative to pipeline breadth, and specialty-pharma commercial model.

TypeDirect peer
Description

U.S.-based specialty generics and specialty pharma company operating across injectables, oral solids, and biosimilars. Comparable to Hyloris for its 505(b)(2) and complex generics expertise, broad pipeline diversification, and reliance on U.S. commercialization partnerships.

9Endo International
TypeBroad incumbent
Description

U.S. specialty pharmaceutical company with focus on sterile injectables, generic pharmaceuticals, and specialty branded products. Overlaps with Hyloris's injectable formulation focus and reformulation-driven pipeline model.

TypeBroad incumbent
Description

India-based global pharmaceutical company with significant specialty generics, complex injectables, and biosimilars portfolio. Comparable to Hyloris for complex generics/specialty strategy at greater geographic scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hyloris Pharmaceuticals

Specialty Pharmaceuticalshyloris.com

Hyloris Pharmaceuticals is a Belgian specialty pharma that develops reformulated, repurposed, and select NCE medicines using the FDA 505(b)(2) pathway, commercializing them globally through licensing partners across hospital, women's health, rare disease, and orphan indications.

What Hyloris Pharmaceuticals does

Hyloris Pharmaceuticals NV/SA is a Belgian specialty pharmaceutical company founded in 2012 and headquartered in Liège, listed on Euronext Brussels (HYL) since June 2020. The company's strategy is to reinvent existing approved medications through reformulation, repurposing, and select new chemical entities, primarily leveraging the FDA's 505(b)(2) regulatory pathway (or equivalents), which reduces clinical burden and development cost versus de novo drug discovery. Proprietary formulation platforms span ready-to-use intravenous formulations, taste-masked oral liquids, and extended-release oral delivery systems, with patent and application coverage extending into the 2035–2046 range.\n\nThe commercial portfolio currently comprises four royalty-generating assets — Maxigesic IV (a fixed-dose paracetamol/ibuprofen IV for post-operative pain, partnered worldwide with AFT Pharmaceuticals and commercialized by Hikma in the US as Combogesic IV), Sotalol IV (AltaThera, US), Podofilox Gel (Padagis, US, launched December 2023), and Tranexamic Acid RTU (Avenacy, US launch H1 2026). Beyond these, the disclosed pipeline numbers 28 announced candidates (more than 30 product candidates in total) across hospital acute care, swallow-impaired populations (pediatric, geriatric, immunocompromised), women's health and urology, orphan/rare diseases (Wilson's disease, AML, LVAD-associated right heart failure), and specialty therapeutic areas; the pipeline is structured into Mavericks (high-clinical-evidence), Core Drivers (near-term revenue catalysts), and Promising Seeds (early-stage).\n\nHyloris operates an asset-light, partner-driven commercialization model: it retains development and regulatory ownership while licensing out or partnering distribution with established pharma players (AFT Pharmaceuticals, Hikma, AltaThera, Padagis, Avenacy, Orion, Rosemont, Grand Life Sciences, Huons, Kuvatris, Purna Female Healthcare, Vaneltix, Wake Forest, ArborMed, RedHill). Revenue mechanics are licensing royalties, milestones (e.g., up to $60M from the RedHill RHB-102 deal), and license/collaboration fees, supplemented by episodic non-dilutive grants from the Walloon Region; the company is EBITDA-negative and reinvests into pipeline expansion through both organic R&D and in-licensing/acquisitions.\n

Hyloris Pharmaceuticals firmographics

Firmographics
Name
Hyloris Pharmaceuticals
Legal name
Hyloris Pharmaceuticals NV/SA
Website
https://hyloris.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Hyloris Pharmaceuticals is a Belgian specialty pharma that develops reformulated, repurposed, and select NCE medicines using the FDA 505(b)(2) pathway, commercializing them globally through licensing partners across hospital, women's health, rare disease, and orphan indications.
Ownership category
akta.pro rank

Hyloris Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions

Keywords

  • Reformulated pharmaceuticals
  • Specialty pharmaceutical development
  • 505(b)(2) regulatory pathway
  • Intravenous drug formulations
  • Pharmaceutical licensing partnerships

Where Hyloris Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Liège
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Hyloris Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Royalty Income from Partnered Products: Three partnered commercial-stage products generate royalty income: Sotalol IV (FDA-approved, commercialized by AltaThera in US), Maxigesic IV (licensed in 100+ countries, marketed in 30+ countries), and Podofilox Gel (FDA approved, launched by Padagis in December 2023). Tranexamic Acid IV RTU also recently approved in US with launch planned for first half 2026.
  2. Milestone Payments: Up to $60 million in potential milestone payments plus royalties from licensing RHB-102 (Bekinda) to Hyloris from RedHill Biopharma, demonstrating potential for additional milestone-based revenue from product acquisitions.
  3. Equity Financing: The company raised EUR 15.0 million in April 2022 through private placement to fund development of new product candidates and accelerate in-house R&D activities. Additional non-dilutive funding of EUR 1 million received from Walloon Region for HY-083 development.

Pricing tiers

ModelBillingPrice
OtherOtherProducts commercialized through partner network; pricing managed by distribution partners

Go-to-market motion1 record

Distribution channels6 records

Marketing channels5 records

Hyloris Pharmaceuticals product offering

Product offering

Core offering

Hyloris Pharmaceuticals is a specialty pharmaceutical company that develops reformulated, repurposed, and new chemical entity (NCE) medicines primarily using the FDA's 505(b)(2) regulatory pathway. Its proprietary portfolio spans more than 30 products including ready-to-use (RTU) intravenous formulations, taste-masked oral liquids, extended-release oral formulations, and novel drug delivery systems across hospital/acute care, women's health, cardiology, and rare diseases. Four commercial products (Maxigesic IV, Sotalol IV, Podofilox Gel, and Tranexamic Acid RTU) generate royalty income through pharmaceutical partners worldwide.

Product overview

Hyloris Pharmaceuticals is a specialty pharma company with a broad portfolio of reformulated, repurposed, and new chemical entity (NCE) medicines organized across three strategic focus groups: Mavericks (high-potential products with clinical evidence), Core Drivers (catalyst products building near-term recurring revenue), and Promising Seeds (early-stage products pending clinical validation). The company has 4 commercial products delivering royalty income: Maxigesic IV (non-opioid post-operative pain), Sotalol IV (atrial fibrillation), Podofilox Gel (HPV warts), and Tranexamic Acid RTU (bleeding). Beyond the 28 publicly announced products, Hyloris has initiated additional early-stage development activities, bringing the total pipeline to more than 30 products. The development strategy primarily leverages the FDA's 505(b)(2) pathway for reformulated pharmaceuticals where safety and efficacy have already been established.

Differentiator

Problem solved

Functional benefit

Brands

  • Maxigesic IV: Differentiated proprietary intravenous fixed-dose combination of paracetamol and ibuprofen for post-operative pain treatment, partnered worldwide with AFT Pharmaceuticals
  • Sotalol IV
  • XTRAZA
  • Alenura

Products and services

  • Maxigesic IV Proprietary intravenous fixed-dose combination of 1,000 mg paracetamol and 300 mg ibuprofen for effective, opioid-sparing treatment of acute pain in hospital settings. Partnered worldwide with AFT Pharmaceuticals (excluding Australia and New Zealand); commercialized in the U.S. by Hikma under the trade name Combogesic IV. Licensed in 100+ countries, approved in 50+ countries, marketed in 30+ countries.
  • Sotalol IV Intravenous formulation of the established antiarrhythmic sotalol developed to enable safe and efficient initiation of sotalol therapy in patients with atrial fibrillation or ventricular arrhythmias. FDA-approved and commercialized in the U.S. by AltaThera for treatment of documented life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm.
  • Podofilox Gel 0.5% podofilox topical gel; the first generic equivalent to Condylox gel in the U.S., developed for treatment of external genital and perianal warts caused by HPV. Launched by Padagis in the U.S. in December 2023.
  • Tranexamic Acid RTU Ready-to-use intravenous formulation of tranexamic acid designed to eliminate the need for reconstitution and dilution prior to administration. FDA-approved in June 2025; exclusive US commercialization partner is Avenacy, with U.S. launch planned for H1 2026; partnered with Orion for European markets.
  • HY-094 (Next-Generation IV Iron) Next-generation intravenous iron product candidate and new chemical entity (NCE) for treatment of iron deficiency anemia in adults. Co-developed with AFT Pharmaceuticals for global commercialization and partnered with Grand Life Sciences Group for China. Has completed Phase 2b development and is advancing toward Phase 3 clinical trials. Proprietary IP with exclusive global human-use license secured.
  • Milrinone ER Proprietary extended-release oral formulation of milrinone for treatment of right heart failure in patients with left ventricular assist devices (LVAD), providing steady-state exposure for long-term use. FDA Orphan Drug Designation received for LVAD-associated RHF indication; priority patent application filed in 2025 with expected expiry in 2046.
  • Miconazole DB (Miconazole-Domiphen Bromide) Dual-action vaginal cream combining miconazole with domiphen bromide for treatment of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV). Dose-finding Phase 2 study in VVC completed. Intellectual property protection through 2038, 2044, and 2045. Developed in partnership with Purna Female Healthcare.
  • Suramin IV Standardized intravenous formulation for Human African Trypanosomiasis (sleeping sickness). In Phase 3 development. May qualify for FDA Priority Review Voucher (HAT is on FDA's tropical diseases list). Phase 2 study on Autism Spectrum Disorder completed. Developed in partnership with Kuvatris Therapeutics.
  • Alenura Ready-to-use intravesical therapy combining alkalinized lidocaine with heparin for adults with interstitial cystitis/bladder pain syndrome (IC/BPS) acute pain flares. Currently in Phase 2 clinical development in partnership with Vaneltix. Multiple patents and applications with maximum expiry in 2038.
  • TXA Oromucosal Solution (XTRAZA) Proprietary tranexamic acid oral rinse designed for dental procedures in patients taking anticoagulants. Randomized, double-blind, multicenter, placebo-controlled Phase 3 trial ongoing with results expected in 2026. U.S. patents granted and pending; expected expiry in 2039. Partnered with Colonis Pharma (UK), Huons Co., Ltd. (South Korea), and AFT Pharmaceuticals in various territories.
  • Metolazone IV First injectable formulation of metolazone designed for hospital use in patients with acute decompensated heart failure and severe fluid overload. Registration batches initiated, clinical completion anticipated in 2026. Patents and pending applications including lyophilized formulation protection; expiry 2044.
  • Valacyclovir Oral Suspension Differentiated valacyclovir powder for oral suspension designed for patients who have difficulty swallowing tablets. NDA submitted to FDA, Complete Response Letter received due to manufacturing-site issues at the third-party manufacturer; launch timing may shift to 2027. Proprietary formulation protected by U.S. patents expiring 2035 and 2036 and pending applications expected to extend to 2045.
  • Atomoxetine Oral Liquid Reformulated easy-to-dose version of atomoxetine for ADHD treatment designed for patients who struggle to swallow capsules. NDA filed with FDA in early 2026 by commercial partner Rosemont Pharmaceuticals. Multiple patents and pending applications providing potential protection through 2044.
  • Ondansetron ER Once-daily extended-release oral formulation of ondansetron combining immediate-release and extended-release components for nausea and vomiting associated with chemotherapy, radiotherapy, and post-operative recovery. Acquired from RedHill Biopharma alongside the licensing of RHB-102 (Bekinda).
  • Dofetilide IV Differentiated intravenous formulation of dofetilide for treatment of atrial fibrillation and atrial flutter. Pivotal clinical trial completed successfully; U.S. regulatory submission expected Q2 2026. Patents granted with expiry dates between 2039 and 2043, including one-day loading approaches.
  • Phosphate Oral Liquid (HY-088) Oral liquid phosphate product (HY-088) designed to improve treatment of hypophosphatemia through a standardized ready-to-use formulation. First European regulatory filing planned for late H1 2026. Pending patent applications with expected expiry in 2045 and 2046.
  • Pantoprazole IV RTU Differentiated, ready-to-use IV pantoprazole product designed to replace current lyophilized formulations. Partnership with Orion for European markets announced January 2026. Pending U.S. and international patent applications; expected expiry 2045.
  • HY-074 (IV Antiplatelet for Acute Coronary Syndrome) Novel intravenous formulation of a widely used oral antiplatelet therapy for acute coronary syndrome. Registration batches produced; pivotal clinical trial planned for 2026. Patent applications filed with maximum expected expiry in 2043–2044.
  • Aspirin IV Intravenous formulation of acetylsalicylic acid designed to provide rapid and reliable antiplatelet activity in acute coronary syndrome. Pivotal study completed successfully with FDA alignment on regulatory pathway; submission planned for 2026. Multiple U.S. patents on aspirin compositions with expiry 2038-2039.
  • Fusidic Acid Topical Cream Topical antibiotic cream containing 2% fusidic acid; generic equivalent to Fucidin cream for treatment of bacterial skin infections. Regulatory submission in Canada expected in 2026.
  • HY-083 (Idiopathic Rhinitis Intranasal Spray) Potential first-in-class proprietary intranasal spray based on TRPV1 agonist mechanism for treatment of idiopathic rhinitis. Backed by EUR 1 million in non-dilutive funding from the Walloon Region (non-refundable grant plus recoverable cash advance).
  • HY-106 Methanobactin (Wilson's Disease) Novel copper-selective chelator based on methanobactin for treatment of Wilson's disease (a rare inherited metabolic disorder characterized by toxic copper accumulation). First-in-human study planned for 2026. European and Turkish rights licensed from ArborMed.
  • HY-086 / PTX-252 (AML Adjunctive Therapy) Differentiated NCE adjunctive therapy for acute myeloid leukemia (AML) and small cell lung cancer (SCLC). FDA Orphan Drug Designation obtained for AML; Phase 1 preparations underway.
  • RHB-102 (Bekinda) License Licensed RHB-102 (Bekinda) from RedHill Biopharma for up to $60 million in potential milestone payments plus royalties, targeting GLP-1/GIP receptor agonist therapy-associated GI side effects and oncology support indications.

Quantifiable outcome

  • Maxigesic IV licensed in more than 100 countries, approved in over 50 countries, marketed in more than 30 countries
  • +2 more outcomes

Companies that use Hyloris Pharmaceuticals

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles2 records

Hyloris Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Hyloris Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered flagship, core and minor.

  • RedHill BiopharmaflagshipStrategic or Co-development Partner · 27 April 2026Licensed RHB-102 (Bekinda) from RedHill for up to $60 million in potential milestone payments plus royalties. Also acquired Ondansetron ER (extended-release oral ondansetron) product, broadening pipeline into GI/nausea indications. RedHill also reports $4 million investment from Cumberland Pharmaceuticals for 30% stake in Talicia Holdings Inc.
  • OrionflagshipStrategic or Co-development Partner · 19 January 2026Strategic partnership for RTU Pantoprazole IV in European markets. Orion is a significant European pharmaceutical company with established commercialization capabilities across the region. Target launch as of 2028.
  • ArborMedcoreStrategic or Co-development Partner · 30 December 2025Licensed European and Turkish rights to next-generation Wilson's disease candidate (HY-106 Methanobactin) from ArborMed. Wilson's disease is a rare inherited metabolic disorder characterized by toxic copper accumulation.
  • Rosemont PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 29 December 2025Partnership for Atomoxetine Oral Solution in the US market. Also partnered for Valacyclovir Oral Suspension in US. Atomoxetine NDA filed with US FDA in early 2026.
  • Wake Forest UniversitycoreStrategic or Co-development Partner · 12 December 2025Collaboration to develop a therapy for a rare skin disorder. This partnership focuses on an exclusive license option for an innovative topical therapy for a rare genetic skin disorder, with potential to qualify for Orphan Drug Designation.
  • OrioncoreChannel Partner/ Reseller/ Distributor · 28 October 2025Partnership to bring Tranexamic Acid RTU to key European markets. This complements the January 2026 partnership for Pantoprazole IV RTU.
  • Grand Life Sciences GroupcoreChannel Partner/ Reseller/ Distributor · 27 October 2025Partnership for HY-094 (next-generation IV iron product) in China. HY-094 is a new chemical entity for treatment of iron deficiency anemia, currently advancing toward Phase 3 after completing Phase 2b development.
  • Huons Co., Ltd.minorChannel Partner/ Reseller/ Distributor · 22 August 2025Exclusive licensing agreement for XTRAZA in South Korea. XTRAZA is a proprietary tranexamic acid oral rinse designed for dental procedures in patients taking anticoagulants.
  • Kuvatris TherapeuticscoreStrategic or Co-development Partner · 23 June 2025Partnership to advance Suramin IV development for Human African Trypanosomiasis (sleeping sickness). Since HAT is on FDA's tropical diseases list, approval could qualify for Priority Review Voucher.
  • QliniQminorChannel Partner/ Reseller/ Distributor · 13 May 2025Partnership for Valacyclovir Oral Suspension covering the Netherlands. Combined with AFT partnership for Valacyclovir in Australia, New Zealand, and Canada.
  • Colonis PharmaminorChannel Partner/ Reseller/ Distributor · 3 February 2025Partnership for XTRAZA (tranexamic acid oral rinse) in the United Kingdom for prevention and treatment of bleeding in patients on anticoagulant therapy undergoing dental procedures.
  • AvenacycoreChannel Partner/ Reseller/ Distributor · 26 December 2024Exclusive US commercialization partner for Tranexamic Acid Ready-to-Use (RTU) IV formulation. FDA approval received in June 2025; US launch planned for first half 2026.
  • Purna Female HealthcarecoreStrategic or Co-development Partner · 30 January 2024Partnership to develop Miconazole-Domiphen Bromide vaginal cream for vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV). Positive Phase 2 trial results announced in January 2024.
  • PadagiscoreChannel Partner/ Reseller/ Distributor · 4 December 2023Padagis launched Podofilox Gel (first generic equivalent to Condylox gel) in the US market in December 2023 for treatment of external genital and perianal warts caused by HPV.
  • AFT PharmaceuticalsflagshipStrategic or Co-development Partner · 31 March 2022AFT Pharmaceuticals is a key strategic partner for Maxigesic IV worldwide (excluding Australia and New Zealand). Also co-develops HY-094 (IV iron product for iron deficiency anemia) for global commercialization. Additionally partnered for XTRAZA (tranexamic acid oral rinse) and Valacyclovir in various territories. Maxigesic IV is licensed in 100+ countries, approved in 50+ countries, and marketed in 30+ countries through this partnership network.
  • Hikma PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 31 March 2022Hikma commercializes Maxigesic IV in the United States under the registered trade name Combogesic IV. This is a key commercial partnership for the US market, one of the world's largest pharmaceutical markets.
  • AltaTheracoreChannel Partner/ Reseller/ Distributor · 31 March 2022AltaThera commercializes Sotalol IV in the US market. Sotalol IV is FDA-approved for treatment of documented life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation patients.
  • VaneltixcoreStrategic or Co-development Partner · 17 October 2021Strategic partnership for Alenura treatment of acute pain in interstitial cystitis. Alenura is a ready-to-use intravesical therapy combining alkalinized lidocaine with heparin for adults with IC/BPS pain flares.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Hyloris Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Lannett: U.S. specialty generic pharmaceutical company focused on oral solids, topicals, and specialty formulations. Similar to Hyloris in pipeline breadth vs. headcount and focus on niche reformulated products.
  • Padagis: U.S. specialty generics company (formerly Perrigo's generics unit) commercializing topical, oral, and injectable generics. Direct peer given commercial partnership on Podofilox Gel and overlapping focus on value-added generics and specialty pharmaceutical products.
  • AFT Pharmaceuticals: Specialty pharmaceutical company headquartered in New Zealand focused on reformulated and repurposed medicines with global commercialization partnerships. Direct comparable to Hyloris in product strategy and partnership-driven GTM; Hyloris's flagship Maxigesic IV is co-developed with AFT.
  • ANI Pharmaceuticals: U.S. specialty pharmaceutical company focused on niche generics, 505(b)(2) products, and contract manufacturing. Closely comparable to Hyloris in reformulation focus, small headcount relative to pipeline breadth, and specialty-pharma commercial model.
  • Amneal Pharmaceuticals: U.S.-based specialty generics and specialty pharma company operating across injectables, oral solids, and biosimilars. Comparable to Hyloris for its 505(b)(2) and complex generics expertise, broad pipeline diversification, and reliance on U.S. commercialization partnerships.

Broad incumbents

  • Hikma Pharmaceuticals: Large multinational specialty pharmaceutical company with broad generics, injectables, and branded pharma portfolio. Comparable to Hyloris as a U.S. commercial partner on Combogesic IV and for overlapping injectable/specialty strategy at greater scale.
  • Mallinckrodt: Global specialty pharmaceutical company with branded and specialty generics franchises, including hospital injectables and reformulated products. Comparable to Hyloris's hospital/acute-care injectable focus.
  • Endo International: U.S. specialty pharmaceutical company with focus on sterile injectables, generic pharmaceuticals, and specialty branded products. Overlaps with Hyloris's injectable formulation focus and reformulation-driven pipeline model.
  • Lupin Pharmaceuticals: India-based global pharmaceutical company with significant specialty generics, complex injectables, and biosimilars portfolio. Comparable to Hyloris for complex generics/specialty strategy at greater geographic scale.

Regional players

  • Theramex: European-based specialty pharmaceutical company focused on women's health and other specialty therapeutic areas. Comparable to Hyloris's women's health and specialty therapeutic area strategy, primarily serving European markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Hyloris Pharmaceuticals social profiles

Digital presence

Hyloris Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hyloris Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

Hyloris Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Hyloris Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hyloris Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyloris Pharmaceuticals

What does Hyloris Pharmaceuticals do?

Hyloris Pharmaceuticals is a specialty pharmaceutical company that develops reformulated, repurposed, and new chemical entity (NCE) medicines primarily using the FDA's 505(b)(2) regulatory pathway. Its proprietary portfolio spans more than 30 products including ready-to-use (RTU) intravenous formulations, taste-masked oral liquids, extended-release oral formulations, and novel drug delivery systems across hospital/acute care, women's health, cardiology, and rare diseases. Four commercial products (Maxigesic IV, Sotalol IV, Podofilox Gel, and Tranexamic Acid RTU) generate royalty income through pharmaceutical partners worldwide.

Is Hyloris Pharmaceuticals a public or private company?

Hyloris Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Hyloris Pharmaceuticals founded?

Hyloris Pharmaceuticals was founded in 2012. It employs 51 to 100 people.

Where is Hyloris Pharmaceuticals based?

Hyloris Pharmaceuticals is headquartered in Liège, Belgium, in the Europe region.

How does Hyloris Pharmaceuticals make money?

Three revenue lines are on record. Royalty Income from Partnered Products are the primary driver. The others are milestone Payments and equity Financing.

Who are Hyloris Pharmaceuticals's main competitors?

Direct peers on record are Lannett, Padagis, AFT Pharmaceuticals, ANI Pharmaceuticals and Amneal Pharmaceuticals. Broad incumbents are Hikma Pharmaceuticals, Mallinckrodt, Endo International and Lupin Pharmaceuticals. Theramex is listed as a regional player.

Does Hyloris Pharmaceuticals have an API?

No public API is recorded for Hyloris Pharmaceuticals.

What industry is Hyloris Pharmaceuticals in?

Hyloris Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingHyloris Developments Presents Drug Pipeline and Commercial Growth StrategyHyloris Developments presented its drug pipeline and commercial strategy at the Jefferies Global Healthcare Conference in London. HY-094 secured Phase 3 IND clearance, and four products are commercialized, with initial royalties from Tranexamic Acid IV RTU. Three programs were discontinued, including XTRAZA's US Phase 3, as investment shifts toward stronger programs.The future of tradingHyloris Signs Exclusive Distribution Deal With AFT Pharmaceuticals for Phosphate Oral Liquid in Five MarketsHyloris signed an exclusive distribution agreement with AFT Pharmaceuticals for phosphate oral liquid in five international markets. The deal covers five markets, with no further details provided on the agreement.The future of tradingHyloris Announces Final Conversion Price for EUR 1 Million in Convertible BondsHyloris announced the final conversion price for its EUR 1 million convertible bonds on November 7, 2026. The announcement was made by Hyloris Developments SA, with the original content published on that date.The future of tradingHyloris Sets Final Conversion Price for EUR 1 Million Convertible BondsHyloris set the final conversion price for its EUR 1 million convertible bonds at EUR 4.8653, a 33.33% premium to the EUR 3.6491 reference VWAP over three trading days. The offering was announced on October 28, 2026, and issuance will occur at Hyloris' request no later than 15 days after its 2026 annual financial report is published.The future of tradingHyloris Sets Debt Conversion Price at EUR 4.8653 per ShareHyloris set the conversion price for its EUR 1 million convertible bonds at EUR 4.8653 per ordinary share, a 33.33% premium to the three-day VWAP. Subscription and issuance will occur upon request, no later than 15 days after publication of its 2026 annual financial report.Stock TitanRedHill 2025 results: equity turns positiveRedHill Biopharma reported full-year 2025 financial results, ending the year with positive equity of $4.3 million compared to a capital deficiency of $4.7 million at year-end 2024. The company completed strategic transactions including a $4 million investment from Cumberland Pharmaceuticals for a 30% stake in newly formed Talicia Holdings Inc. and licensed RHB-102 (Bekinda) to Hyloris Pharmaceuticals for up to $60 million in potential milestone payments plus royalties. Operating loss from continuing operations was $7.9 million while the company advanced its R&D pipeline including opaganib in a Phase 2 prostate cancer study with Bayer's darolutamide and received positive FDA feedback on RHB-204's pathway for Crohn's disease treatment.openPR.comIntravenous (IV) Ibuprofen Market Outlook 2026-2033: Growth Drivers, Share, And Trends As Revealed In New Report |Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A.Coherent Market Insights has released a market research report on the global intravenous (IV) ibuprofen market, projecting the market to grow from USD 7.96 billion in 2026 to USD 13.12 billion by 2033, representing a compound annual growth rate (CAGR) of 7.4%. The report provides segmentation by indication, strength, age group, and distribution channel, along with competitive analysis of key players including Cumberland Pharmaceuticals, Hyloris Pharmaceuticals, and Hikma Pharmaceuticals. It also includes regional market analysis covering North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.FiercePharmaFDA fires off another manufacturing-related CRL, this one to HylorisThe FDA has rejected Hyloris Pharmaceuticals' antiviral valacyclovir oral suspension for herpes simplex and varicella zoster viruses via a Complete Response Letter (CRL), citing inspection issues at the company's third-party manufacturer in Greece that had received the FDA's most severe "official action indicated" (OAI) classification. The manufacturer has paused production for the U.S. market while continuing output for other regions, and Hyloris is working on a manufacturing solution. The FDA requires a cGMP inspection and preapproval inspection before the application could be approved, along with additional safety data from clinical and nonclinical studies across all tested indications.MarketScreenerHyloris Pharmaceuticals, Wake Forest University to Develop Rare Skin Disorder TherapyHyloris Pharmaceuticals has partnered with Wake Forest University to develop a therapy for a rare skin disorder. This collaboration aims to leverage expertise in creating a novel treatment, potentially enhancing the therapeutic options available for affected patients.KivoRegulatory Data Management In Life SciencesThe article discusses the critical importance of unified regulatory data management platforms in the life sciences industry to replace fragmented legacy systems like spreadsheets. It highlights Kivo as a provider offering solutions that consolidate Quality Management Systems (QMS), Regulatory Information Management (RIM), and electronic Trial Master Files (eTMF) into a single source of truth. The text presents case studies from clients Elpida, Hyloris, and Elevar Therapeutics to demonstrate how adopting such platforms accelerates development timelines and ensures compliance with global regulations.